Britain's GSK is set to acquire RAPT Therapeutics for $2.2 billion. This move brings the experimental food allergy drug ozureprubart into GSK's portfolio. The deal marks a significant step for GSK's new CEO. GSK aims to strengthen its offerings and offset revenue from expiring patents. The acquisition includes global rights to ozureprubart, excluding certain Asian regions.
